Immunohistochemical Analysis of Prurigo Nodularis in 209 Patients: Clinicopathological Analysis between Atopic and Non-Atopic Patients and between Treatment Response Groups

Hyun Jeong Byun, Donghwi Jang, Dong-Youn Lee, Jun-Mo Yang

Department of Dermatology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

**Background:** Prurigo nodularis (PN) is a highly pruritic disease that significantly impairs patient quality of life. Although the mechanism that causes pruritus is not clear, one hypothesis argues that neural hyperplasia, mast cell, and Merkel cell neurite complexes may be associated with PN pathogenesis.

**Objective:** The objective of this study was to analyze whether special staining outcomes differed depending on the presence of atopic dermatitis (AD) and treatment response.

**Methods:** A total of 209 patients diagnosed with PN was analyzed retrospectively. Patients were divided into two groups according to presence or past history of AD and by treatment response. Histopathologic features were obtained using the following stains: Giemsa, S-100, neuron-specific enolase, cytokeratin (CK)-20, CAM5.2, and CK8/CK18.

**Results:** A total of 126 patients (60.29%) had AD, and 68 (32.54%) showed clinical improvement. There were no statistically significant differences in the staining results between the PN groups with AD (PN c AD) and without AD (PN s AD). Additionally, there were no statistically significant differences in staining results between the improved and non-improved groups.

**Conclusion:** Implementing the special stains helped to identify PN pathogenesis. Because there were no statistically significant differences in the special stain results between the improved and non-improved groups, we conclude that mast cell proliferation, neural hyperplasia, and Merkel cell hyperplasia may not have a significant effect on treatment response.

-**Keywords**- Atopic dermatitis, Mast cells, Merkel cells, Nerve fibers, Prurigo

**INTRODUCTION**

Prurigo nodularis (PN) is a highly pruritic, hyperkeratotic papule and nodular disease. PN is common in the 50 to 60 years age group; however, it can also develop in younger people in association with atopic dermatitis (AD). PN significantly impairs quality of life, which can cause psychological distress and sleep disturbance. Repeated scratching of the lesions leads to excoriation and lichenification, mainly on the extensor surfaces, trunk, or lower extremities. PN is associated with a wide range of diseases including AD, various infectious diseases, chronic kidney disease, malignancies, and neurological diseases. Thus, PN is sometimes considered to be a clinical pattern induced by chronic pruritus and repeated scratching and common histopathologic presentations include orthohyperkeratosis, acanthosis, parakeratosis, papillary dermal fibrosis with perivascular inflammatory infiltrations, and characteristic neural hypertrophy. Several previous studies have reported changes in nerve, Merkel,
and mast cells. Although the mechanism of pruritus is not clear, one hypothesis suggests that neural hyperplasia, mast cell, and Merkel cell neurite complexes may be associated with PN pathogenesis. The objective of this study was to analyze whether special staining outcomes differed according to clinical features such as presence of AD and treatment response.

**MATERIALS AND METHODS**

This was a retrospective study using electronic medical records. The ethical committees of Samsung Medical Center approved this study (approval number: 2002-10-009, 2009-12-053). Subjects included were patients who visited the Department of Dermatology at Samsung Medical Center from May 2012 to May 2016 and underwent skin punch biopsy with special staining under clinical diagnosis of PN. A total of 243 patients were clinically suspected of PN, and underwent skin punch biopsy and assessment through several special stains: Giemsa, S-100, neuron-specific enolase (NSE), cytokeratin (CK)-20, CAM5.2, and CK8/CK18. We excluded 34 patients who were diagnosed with diseases other than PN such as capillary hemangioma, bullous pemphigoid, or lichen simplex chronicus; thus, 209 patients were analyzed (Fig. 1).

When patients visited the clinic, the physician first took their medical history including AD history. Next, skin biopsy was performed with special stains. On the same day, oral antihistamines with topical 0.1% methylprednisolone and topical 0.1% tacrolimus were prescribed. Two weeks later, the physician checked the skin biopsy results and adjusted the antihistamines as needed. Patients were followed-up every two to four weeks for six months, and antihistamine prescriptions were adjusted as needed. Signs of improvement included diminished itching or relieved cutaneous lesions such that the antihistamine treatment frequency could be reduced or stopped. Patients with minimal clinical symptom change in their skin lesions or who required additional antihistamines during a follow-up appointment were considered to have no improvement in their condition. Treatment with topical 0.1% methylprednisolone and topical 0.1% tacrolimus ointment was maintained for all patients for six months. Patients were divided into two groups according to presence or past history of AD and according to treatment response. Histopathologic features were obtained from hematoxylin and eosin (H&E) stained slides and from the other six special stains. The chi-square test, Fisher’s exact test, and logistic regressions were used, and all statistical analyses were performed using SAS version 9.4 (SAS Institute, Cary, NC, USA).

**RESULTS**

A total of 209 patients were included in the analyses. Males accounted for 52.63% of the study sample. The average age of onset for all patients was 52.96 years. The average age of onset was 50.19 years for female patients and 55.45 years for male patients, which is significantly different ($p=0.017$). The majority of patients (126/209; 60.29%) had AD or a history of AD. The average AD patient age was 52.78 years, and the average age of patients without AD was 53.24 years; this difference was not statistically significant ($p=0.838$). Among the 209 patients diagnosed with PN after skin biopsy, 75 were lost to follow-up within 3 months. While 68 patients experienced...
clinical improvement, 66 patients showed no improvement within 6 months (Fig. 1). Clinical improvement was observed in 68 patients (32.54%) (Table 1), but the improvement status of the 75 patients who were lost to follow-up is unknown. Thus, when analyzing the 134 patients with more than 3 months of follow-up data, 50.75% showed clinical improvement.

Skin punch biopsy with six special stains was conducted. Giemsa staining was performed to identify mast cell proliferation, and S-100 and NSE were used to identify neural hyperplasia. CK-20, CAM5.2, CK8/CK18 stains were used to observe Merkel cell hyperplasia. With Giemsa staining, mast cell proliferation was seen in 8.1% of patients (Table 2). S-100 stain was positive for nerve proliferation in 15.3% of patients and NSE was positive in 27.3% of patients, with neural hyperplasia being observed in 32.1% (n=67; Table 2). CK-20, CAM5.2, and CK8/CK18 were positive in 0.96%, 17.7%, and 43.1% of patients, respectively, and Merkel cell hyperplasia was observed in 61.2% (n=128; Table 2).

The relationship between special staining outcomes and AD history was analyzed. Giemsa stain yielded a statistically significant difference between the PN groups with AD (PN AD) and PN groups without AD (PN S AD) (p=0.0280; Table 3). In logistic regression models, Giemsa stain was expressed significantly less in PN AD patients than PN S AD patients (odds ratio=0.0347). The relationship between special staining outcomes and treatment response were also analyzed. When analyzing both 209 patients including patients who lost follow up, and 134 patients without them, we found no statistically significant differences between the improved and non-improved groups (Table 3).

**DISCUSSION**

PN is known to be induced by pricking and scratching, secondary to itching. A number of pathways have been suggested to explain heightened perception to itch and touch in PN patients. These include neurochemical changes in cutaneous nerves in the lesions, the spinal cord, and the central nervous system. PN lesions show nerve hyperplasia and elevated numbers of cutaneous nerve fibers, as indicated by positive staining for neuropeptides such as substance P and calcitonin gene-related peptide (CGRP). A previous report indicated that increased CGRP and substance P-immunoreactive nerve fibers is a characteristic feature of PN. Nerve growth factor, which is released from mast cells, is overexpressed in PN lesions and may induce hypersecretion of neuropeptides, such as substance P and calcitonin CGRP, from sensory fibers, resulting in neuropeptide deposition in pruritic nodules. Neuropeptides promote mast cell degranulation and release of mediators like histamines, which not only induces itching in the skin, but also increases fibroblast proliferation and collagen synthesis that causes collagen remodeling. Increased Merkel cell density has also been reported to be associated with neuronal proliferation in PN lesions because they compo-

---

**Table 1.** Clinical characteristics of patients with prurigo nodularis (total=209)

| Clinical feature          | Value          |
|---------------------------|----------------|
| Mean age of onset (yr)    |                |
| Total                     | 52.96 (15.93)  |
| Male                      | 55.45 (14.60)  |
| Female                    | 50.19 (17.00)  |
| Sex                       |                |
| Male                      | 110 (52.63)    |
| Female                    | 99 (47.37)     |
| Male:female               | 1:1            |
| Atopic dermatitis         |                |
| Atopic                    | 126 (60.29)    |
| Non-atopic                | 83 (39.71)     |
| Treatment response        |                |
| Improvement               | 68 (32.54)*    |
| No improvement            | 66 (31.58)     |
| Follow-up loss            | 75 (35.89)     |

Values are presented as mean (standard deviation) or number (%). *When 75 patients who were lost to follow-up were excluded, 50.75% clinically improved.

**Table 2.** Special staining results for patients with prurigo nodularis

| Special stain                | No. of specimens with positive stains (n=209) | No. of specimens with positive stains (n=134) |
|-----------------------------|-----------------------------------------------|-----------------------------------------------|
| Mast cell proliferation     |                                              |                                              |
| Giemsa                      | 17 (8.1)                                     | 13 (9.7)                                     |
| Total                       | 17 (8.1)                                     | 13 (9.7)                                     |
| Neural hyperplasia          |                                              |                                              |
| S-100                       | 32 (15.3)                                    | 19 (14.2)                                    |
| NSE                         | 57 (27.3)                                    | 35 (26.1)                                    |
| Total                       | 67 (32.1)                                    | 41 (30.6)                                    |
| Merkel cell hyperplasia     |                                              |                                              |
| CK-20                       | 2 (1.0)                                      | 2 (1.5)                                      |
| CAM5.2                      | 37 (17.7)                                    | 24 (17.9)                                    |
| CK8 and CK18                | 90 (43.1)                                    | 58 (43.3)                                    |
| Total                       | 128 (61.2)                                   | 83 (61.9)                                    |

Values are presented as number (%). NSE: neuron-specific enolase, CK: cytokeratin.
the relationship between special staining results and clinical factors.

### Table 3

| Variable                  | Mast cell proliferation | Neural hyperplasia | Merkel cell hyperplasia |
|---------------------------|-------------------------|--------------------|-------------------------|
|                          | Giemsa positive | p-value | Odds ratio | S-100 positive | p-value | NSE positive | p-value | CK-20 positive | p-value | CAM 5.2 positive | p-value | CK8 and CK18 positive | p-value |
| Atopic dermatitis (n=209) | 17 0.0280*          | 0.0347*          |            | 32 0.9088    | 57       | 0.6651      | 2       | 0.6377      | 37 | 0.9097       | 90       | 0.8323          |
| Present (n=126)           | 6 0.35 (35.3)        | 0.7742           |            | 19 0.59 (59.4) | 33 0.57 (57.9) | 1 0.50 (50.0) | 22 0.59 (59.5) | 55 0.61 (61.1) |
| Not present (n=83)        | 11 0.64 (64.7)       |                |            | 13 0.40 (60.6) | 24 0.42 (62.1) | 1 0.50 (50.0) | 15 0.40 (50.5) | 35 0.39 (39.8) |
| Treatment response (n=209) | 17 0.7742           |                |            | 32 0.1619    | 57       | 0.8565      | 2       | 0.1048      | 37 | 0.7099       | 90       | 0.4962          |
| Improved (n=68)           | 5 0.29 (34.8)        |                |            | 21 0.19 (21.9) | 18 0.31 (28.6) | 2 0.10 (100) | 13 0.35 (35.1) | 27 0.30 (30.0) |
| Non improved (n=141)      | 12 0.70 (69.6)       |                |            | 25 0.78 (78.1) | 39 0.68 (68.4) | 0 0      | 24 0.64 (64.9) | 63 0.70 (70.0) |
| Treatment response (n=134) | 13 0.35 (35.2)       |                |            | 19 0.1907    | 35       | 0.9252      | 2       | 0.4964      | 24 | 0.7114       | 58       | 0.3962          |
| Improved (n=68)           | 5 0.38 (35.3)        |                |            | 7 0.36 (36.8) | 18 0.51 (51.4) | 2 0.10 (100) | 13 0.54 (54.2) | 27 0.46 (46.0) |
| Non improved (n=66)       | 8 0.61 (61.5)        |                |            | 12 0.63 (63.2) | 17 0.48 (48.6) | 0 0      | 11 0.45 (45.8) | 31 0.53 (53.4) |

Values are presented as number only or number (%). NSE: neuron-Specific Enolase, CK: cytokeratin. *Statistically significant (p<0.05).

This is the first study to examine the relationship between special staining results and clinical factors. This study may have a selection bias because it consists of patients at a single tertiary hospital. Also, since this is a retrospective study, the degree of improvement was not evaluated with numerical scales or patient surveys, but according to medication change. This study may have a selection bias because it consists of patients at a single tertiary hospital. Also, since this is a retrospective study, the degree of improvement was not evaluated with numerical scales or patient surveys, but according to medication change. This study may have a selection bias because it consists of patients at a single tertiary hospital. Also, since this is a retrospective study, the degree of improvement was not evaluated with numerical scales or patient surveys, but according to medication change.
special staining outcomes and clinical features of PN. Through special staining analyses, neural hyperplasia, Merkel cell hyperplasia, and mast cell proliferation were observed, and our results are consistent with the previous literature. Lastly, we did not find any statistically significant differences in special staining results between the PN c AD and PN s AD groups nor between the improved and non-improved groups. Therefore, we concluded that mast cell proliferation, neural hyperplasia, and Merkel cell hyperplasia may not have a significant effect on treatment response or presence of AD.

CONFLICTS OF INTEREST
The authors have nothing to disclose.

FUNDING SOURCE
None.

DATA SHARING STATEMENT
The data that support the findings of this study are available from the corresponding author upon reasonable request.

ORCID
Hyun Jeong Byun, https://orcid.org/0000-0002-4354-5655
Donghwi Jang, https://orcid.org/0000-0002-3495-4772
Dong-Youn Lee, https://orcid.org/0000-0003-0765-9812
Jun-Mo Yang, https://orcid.org/0000-0003-0656-8046

REFERENCES
1. Kowalski EH, Kneiber D, Valdebran M, Patel U, Amber KT. Treatment-resistant prurigo nodularis: challenges and solutions. Clin Cosmet Investig Dermatol 2019;12:163-172.
2. Tan WS, Tey HL. Extensive prurigo nodularis: characterization and etiology. Dermatology 2014;228:276-280.
3. Weisshaar E, Szeptiewski JC, Darsow U, Misery L, Wallengren J, Mettang T, et al. European guideline on chronic pruritus. Acta Derm Venereol 2012;92:563-581.
4. Tessari G, Dalle Vedove C, Loschiavo C, Tessitore N, Rugiu C, Lupo A, et al. The impact of pruritus on the quality of life of patients undergoing dialysis: a single centre cohort study. J Nephrol 2009;22:241-248.
5. Vaidya DC, Schwartz RA. Prurigo nodularis: a benign dermatosis derived from a persistent pruritus. Acta Dermatovenerol Croat 2008;16:38-44.
6. Ikting A, Grundmann S, Chatzigeorgakidis E, Phan NQ, Klein D, Ständer S. Prurigo as a symptom of atopic and non-atopic diseases: aetiologic survey in a consecutive cohort of 108 patients. J Eur Acad Dermatol Venereol 2013;27:550-557.
7. Saporito L, Florena AM, Colomba C, Pampinella D, Di Carlo P. Prurigo nodularis due to Mycobacterium tuberculosis. J Med Microbiol 2009;58(Pt 12):1649-1651.
8. Hayani K, Weiss M, Weisshaar E. Clinical findings and provision of care in haemodialysis patients with chronic itch: new results from the German Epidemiological Haemodialysis Itch Study. Acta Derm Venereol 2016;96:361-366.
9. Kestner RI, Ständer S, Osada N, Ziegler D, Metze D. Acquired reactive perforating dermatosis is a variant of prurigo nodularis. Acta Derm Venereol 2017;97:249-254.
10. Khaled A, Sfia M, Fazaa B, Kourda N, Zerrani R, Baccouche K, et al. [Chronic prurigo revealing an angio-immunoblastic T cell lymphoma]. Tunis Med 2009;87:534-537.
11. Seshadri P, Rajan SJ, George IA, George R. A sinister itch: prurigo nodularis in Hodgkin lymphoma. J Assoc Physicians India 2009;57:715-716.
12. Weigelt N, Metze D, Ständers S. Prurigo nodularis: systematic analysis of 58 histological criteria in 136 patients. J Cutan Pathol 2010;37:578-586.
13. Silverberg JI. Nummular eczema, lichen simplex chronicus, and prurigo nodularis. In: Kang S, Amagai M, Bruckner AL, Enk AH, Margolis DJ, McMichael AJ, et al., editors. Fitzpatrick’s dermatology. 9th ed. New York: McGraw Hill Education, 2019:385-394.
14. Fernandez-Flores A. CD10 immunohistochemistry in prurigo nodularis. Histopathology 2008;52:642-643.
15. Johansson O, Liang Y, Emttestam L. Increased nerve growth factor- and tyrosine kinase A-like immunoreactivities in prurigo nodularis skin – an exploration of the cause of neurohyperplasia. Arch Dermatol Res 2002;293:614-619.
16. Johansson O, Liang Y, Marcusca JA, Reimert CM. Eosinophil cationic protein- and eosinophil-derived neurotoxin/eosinophil protein X-immunoreactive eosinophils in prurigo nodularis. Arch Dermatol Res 2000;292:371-378.
17. Liang Y, Jacobi HH, Reimert CM, Haak-Frendscho M, Marcusca JA, Johansson O. CGRP-immunoreactive nerves in prurigo nodularis—an exploration of neurogenic inflammation. J Cutan Pathol 2000;27:359-366.
18. Nahass GT, Penneys NS. Merkel cells and prurigo nodularis. J Am Acad Dermatol 1994;31:86-88.
19. Harris B, Harris K, Penneys NS. Demonstration by S-100 protein staining of increased numbers of nerves in the papillary dermis of patients with prurigo nodularis. J Am Acad Dermatol 1992;26:56-58.
20. Liang Y, Marcusca JA, Jacobi HH, Haak-Frendsco M, Johansson O. Histamine-containing mast cells and their relationship to NGF-immunoreactive nerves in prurigo nodularis: a reappraisal. J Cutan Pathol 1998;25:189-198.
21. Goneberg DA, Serowka F, Peckenschneider N, Artuc M, Grützkau A, Fischer A, et al. Gene expression and regulation of nerve growth factor in atopic dermatitis mast cells and the human mast cell line-1. J Neuroimmunol 2005;161:87-92.
22. Ikoma A, Steinhoff M, Ständer S, Yosipovitch G, Schmelz M. The neurobiology of itch. Nat Rev Neurosci 2006;7: 535-547.
23. Garbuzenko E, Nagler A, Pickholtz D, Gillery P, Reich R, Maquart FX, et al. Human mast cells stimulate fibroblast proliferation, collagen synthesis and lattice contraction: a direct role for mast cells in skin fibrosis. Clin Exp Allergy 2002;32:237-246.
24. Kawakami T, Ando T, Kimura M, Wilson BS, Kawakami Y. Mast cells in atopic dermatitis. Curr Opin Immunol 2009; 21:666-678.
25. Youngblood B, Schanin J, Tomasevic N, Kamboj A. Atopic dermatitis skin biopsies have high numbers of activated mast cells that are inhibited by AK002 after stimulation ex vivo. J Allergy Clin Immunol 2020;145:AB198.